@article{3161793,
    title = "Regional differences observed in the phase 3 trial (ELM-PC 5) with
orteronel (TAK-700) plus prednisone in patients with metastatic
castration-resistant prostate cancer (mCRPC) that has progressed during
or following docetaxel.",
    author = "Fizazi, Karim and Jones, Robert and Oudard, Stephane and Efstathiou, and Eleni and Saad, Fred and De Wit, Ronald and De Bono, Johann Sebastian and and Cruz, Felipe and Fountzilas, George and Ulys, Albertas and Carcano, and Flavio and Agarwal, Neeraj and Agus, David B. and Bellmunt, Joaquim and and Petrylak, Daniel Peter and Lee, Connie and Tejura, Bindu and Borgstein, and Niels Geert and Dreicer, Robert",
    journal = "World Journal of Clinical Oncology",
    year = "2014",
    volume = "32",
    number = "15, S",
    publisher = "Lippincott, Williams & Wilkins",
    doi = "10.1200/jco.2014.32.15_suppl.5042"
}